who makes glp-1 drugs Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care What are GLP-1 Medications and

Research shows that many patients regain weight after discontinuing GLP-1 therapy, which raises questions about whether insurance should cover indefinite use

10.1097/MED.0000000000000835 Curr Opin Endocrinol Diabetes Obes

Insurance Claim With medical bills and inflation on the rise, insurance coverage is a key factor for many patients who are considering these routes for weight loss or disease management

Whether orforglipron's effects on bone health are net positive (through receptor-mediated bone protection) or net negative (through sustained caloric deficit and weight loss reducing mechanical loading on bones) will need to be determined through long-term surveillance studies